Associated Papers
BRAF V600E in cancer: Exploring structural complexities, mutation profiles, and pathway dysregulation.
Bharti J et al.
Experimental Cell Research, 2025
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study.
Nelson BE et al.
Npj Precision Oncology, 2023
Spectrum of BRAF Aberrations and Its Potential Clinical Implications: Insights From Integrative Pan-Cancer Analysis.
Yi Q et al.
Frontiers in Bioengineering and Biotechnology, 2022
35910024 (PubMed )
Supplement: Table2.XLSX › table
Select a paper to view details